Mimicking Lnc-THOR depletion-induced anti-cancer activity, CRISPR/Cas9-induced IGF2BP1 KO potently inhibited NSCLC cell proliferation and migration. Here, IGF2BP1 is linked to non-small cell lung carcinoma.